289 related articles for article (PubMed ID: 20846399)
21. Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro.
Fisher LA; Bessho M; Bessho T
J Biol Chem; 2008 Jan; 283(3):1275-1281. PubMed ID: 18006494
[TBL] [Abstract][Full Text] [Related]
22. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy.
Clingen PH; Wu JY; Miller J; Mistry N; Chin F; Wynne P; Prise KM; Hartley JA
Biochem Pharmacol; 2008 Jul; 76(1):19-27. PubMed ID: 18508035
[TBL] [Abstract][Full Text] [Related]
23. ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.
Sabatella M; Pines A; Slyskova J; Vermeulen W; Lans H
Cell Mol Life Sci; 2020 May; 77(10):2005-2016. PubMed ID: 31392348
[TBL] [Abstract][Full Text] [Related]
24. XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF.
Lehmann J; Seebode C; Smolorz S; Schubert S; Emmert S
Cell Mol Life Sci; 2017 Jun; 74(11):2081-2094. PubMed ID: 28130555
[TBL] [Abstract][Full Text] [Related]
25. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair.
Rahn JJ; Adair GM; Nairn RS
Environ Mol Mutagen; 2010 Jul; 51(6):567-81. PubMed ID: 20658648
[TBL] [Abstract][Full Text] [Related]
26. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
27. Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway.
Zhang N; Liu X; Li L; Legerski R
DNA Repair (Amst); 2007 Nov; 6(11):1670-8. PubMed ID: 17669695
[TBL] [Abstract][Full Text] [Related]
28. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
29. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
30. Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.
Ahmad A; Enzlin JH; Bhagwat NR; Wijgers N; Raams A; Appledoorn E; Theil AF; J Hoeijmakers JH; Vermeulen W; J Jaspers NG; Schärer OD; Niedernhofer LJ
PLoS Genet; 2010 Mar; 6(3):e1000871. PubMed ID: 20221251
[TBL] [Abstract][Full Text] [Related]
31. Removal of reactive oxygen species-induced 3'-blocked ends by XPF-ERCC1.
Fisher LA; Samson L; Bessho T
Chem Res Toxicol; 2011 Nov; 24(11):1876-81. PubMed ID: 22007867
[TBL] [Abstract][Full Text] [Related]
32. Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.
Priya Doss CG; Nagasundaram N
Appl Biochem Biotechnol; 2014 Feb; 172(3):1265-81. PubMed ID: 24158589
[TBL] [Abstract][Full Text] [Related]
33. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
34. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
35. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
36. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Hatch SB; Swift LP; Caporali S; Carter R; Hill EJ; MacGregor TP; D'Atri S; Middleton MR; McHugh PJ; Sharma RA
Int J Cancer; 2014 Mar; 134(6):1495-503. PubMed ID: 23982883
[TBL] [Abstract][Full Text] [Related]
37. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.
Wang AT; Sengerová B; Cattell E; Inagawa T; Hartley JM; Kiakos K; Burgess-Brown NA; Swift LP; Enzlin JH; Schofield CJ; Gileadi O; Hartley JA; McHugh PJ
Genes Dev; 2011 Sep; 25(17):1859-70. PubMed ID: 21896658
[TBL] [Abstract][Full Text] [Related]
38. Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair.
Su Y; Orelli B; Madireddy A; Niedernhofer LJ; Schärer OD
J Biol Chem; 2012 Jun; 287(26):21846-55. PubMed ID: 22547097
[TBL] [Abstract][Full Text] [Related]
39. ERCC1 and XPF expression in human testicular germ cell tumors.
Köberle B; Brenner W; Albers A; Usanova S; Thüroff JW; Kaina B
Oncol Rep; 2010 Jan; 23(1):223-7. PubMed ID: 19956886
[TBL] [Abstract][Full Text] [Related]
40. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
McNeil EM; Melton DW
Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
